Nanotechnology based advanced therapeutic strategies for targeting interleukins in chronic respiratory diseases

Md Sadique Hussain, Parvarish Sharma, Daljeet Singh Dhanjal, Navneet Khurana, Manish Vyas, Neha Sharma, Meenu Mehta, Murtaza M. Tambuwala, Saurabh Satija, Sukhwinder Singh Sohal, Brian.g.g. Oliver, Hari S. Sharma

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)
15 Downloads (Pure)


Both communicable and non-communicable chronic respiratory conditions have accorded for suffering of millions of people of all ages and stated to be leading cause of death, morbidity, economic and social pressures, and disability-adjusted life-years (DALYs) worldwide. These illnesses impair patient's health and negatively impacts families and society, particularly in low and middle-income countries. Chronic respiratory diseases (CRDs) affect different organs of respiratory system, involving airways, parenchyma, and pulmonary vasculature. As the number of respiratory diseases are exponentially escalating but still the stakeholders are not paying attention towards its serious complications. Currently, the treatment being used primarily focusses only on alleviating symptoms of these illness rather delivering the therapeutic agent at target site for optimal care and/or prevention. Lately, extensive research is being conducted on airways and systemic inflammation, oxidative stress, airway, or parenchymal rehabilitation. From which macrophages, neutrophils, and T cells, as well as structural cells as fibroblasts, epithelial, endothelial, and smooth muscle cells have been found to be active participants that are involved in these chronic respiratory diseases. The pathogenesis of all these chronic respiratory diseases gets caused differently via mediators and proteins, including cytokines, chemokines, growth factors and oxidants. Presently, the target of prescription therapies is to reduce the inflammation of airways and relieve the airway contraction. In all studies, cytokines have been found to play an imperative role in fostering chronic airway inflammation and remodelling. Owing to the limitations of conventional treatments, the current review aims to summarize the current knowledge about the chronic respiratory disease and discuss further about the various conventional methods that can be used for treating this ailment. Additionally, it also highlights and discusses about the advanced drug delivery system that are being used for targeting the interleukins for the treatment of CRDs. [Abstract copyright: Copyright © 2021 Elsevier B.V. All rights reserved.]
Original languageEnglish
Article number109637
Number of pages46
JournalChemico-Biological Interactions
Publication statusPublished (in print/issue) - 1 Oct 2021

Bibliographical note

Funding Information:
S. S. Sohal is supported by research grants from Clifford Craig Foundation , Launceston General Hospital , Launceston TAS 7250, Australia.

Publisher Copyright:
© 2021 Elsevier B.V.


  • Interleukins
  • Chronic respiratory diseases
  • drug delivery
  • Drug delivery
  • Interleukins/metabolism
  • Humans
  • Molecular Targeted Therapy/methods
  • Nanomedicine/methods
  • Respiratory Tract Diseases/drug therapy
  • Chronic Disease


Dive into the research topics of 'Nanotechnology based advanced therapeutic strategies for targeting interleukins in chronic respiratory diseases'. Together they form a unique fingerprint.

Cite this